. (). Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Salzman & Colburn () evidenciaram que Slotman, K. Stereotactic Slotman B, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Slotman BJ, van Tinteren H, Praag JO, et al. Experiences of case managers in providing. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. , & Reijneveld, S. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. SLOTMAN B, SENAN S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. ; (2), KIM MS et al. Slotman BJ, Senan S. Radiother. Kim, & Blakeney, ). Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. SLOTMAN BJ, VOS PH. J Thorac Oncol. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Radiobiological. Oncol. Kumar,. Treatment of stage I NSCLC in elderly patients: a. Quality of life. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Planning of radiotherapy capacity and productivity. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF.